Pearson Center for Alcoholism and Addiction Research, The Scripps Research Institute, 10550 North Torrey Pines Road, TPC-5, La Jolla, CA 92037, USA.
Expert Opin Drug Saf. 2010 Jan;9(1):177-88. doi: 10.1517/14740330903512943.
Acamprosate, marketed under the brand name Campral, (Forest Pharmaceuticals, Inc., Saint Louis, MO, USA; Merck Sante s.a.s., Lyon, France) is an orally administered drug approved in the US and throughout much of the world for treating alcohol dependence. Its safety and efficacy have been demonstrated in a number of clinical trials worldwide and as with all pharmacotherapies for alcoholism, it is used in conjunction with psychosocial interventions.
This article reviews the mechanism of action, clinical efficacy and safety of acamprosate in Phase I, II and III randomized controlled trials involving healthy and alcohol-dependent populations using published reports from 1984 to 2009.
This review provides an update of the mechanism of action and the safety and efficacy profile of acamprosate.
Acamprosate appears to act centrally to restore the normal activity of glutamatergic neurotransmission altered by chronic alcohol exposure. Acamprosate's excellent safety profile along with several pharmacokinetic and pharmacodynamic characteristics make it well suited for treating a broad population of alcohol-dependent patients.
丙戊酸钠（商品名 Campral，Forest Pharmaceuticals, Inc.，圣路易斯，密苏里州，美国；Merck Sante s.a.s.，里昂，法国）是一种口服药物，已在美国和世界许多地方获得批准用于治疗酒精依赖。其安全性和疗效已在全球多项临床试验中得到证实，与所有酒精中毒的药物治疗一样，它与心理社会干预相结合使用。
本文综述了丙戊酸钠在涉及健康和酒精依赖人群的 I、II 和 III 期随机对照试验中的作用机制、临床疗效和安全性，使用了 1984 年至 2009 年发表的报告。
本综述提供了丙戊酸钠作用机制以及安全性和疗效的最新信息。
丙戊酸钠似乎通过中枢作用恢复了慢性酒精暴露改变的谷氨酸能神经传递的正常活动。丙戊酸钠的安全性良好，同时具有多种药代动力学和药效学特征，使其非常适合治疗广泛的酒精依赖患者群体。
